CanSino Biologics Inc. (HKG:6185)
Hong Kong
· Delayed Price · Currency is HKD 22.64
+1.68 (8.02%)
Jun 29, 2026, 11:52 AM HKT
CanSino Biologics Employees
CanSino Biologics had 1,134 employees as of December 31, 2025. The number of employees increased by 29 or 2.62% compared to the previous year.
Employees
1,134
Change (1Y)
29
Growth (1Y)
2.62%
Revenue / Employee
1.12M HKD
Profits / Employee
-1.01K HKD
Market Cap
9.10B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Shandong Xinhua Pharmaceutical Company | 7,240 |
| Consun Pharmaceutical Group | 3,115 |
| CF PharmTech | 540 |
| Sihuan Pharmaceutical Holdings Group | 2,843 |
| Luye Pharma Group | 5,221 |
| China Traditional Chinese Medicine Holdings Co. | 14,846 |
| Xuanzhu Biopharmaceutical | 342 |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | 876 |
CanSino Biologics News
- 4 months ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 4 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 4 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 4 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire